| Day 1 - Thu, Sep 11 | ||||
|---|---|---|---|---|
| Agora | ||||
| 09:00-10:17 | ENG Moderated Poster 1 | Hyun-Jai Cho (Seoul National Univ., Korea) | ||
| 09:00-09:07 | Temporal Trends of Patient Characteristics and Clinical Outcomes in Heart Failure Patients: A Systematic Review and Meta-Regression Analysis | Joon-Seok Kim (The Catholic Univ., Korea) | ||
| 09:07-09:14 | Integrating Epigenetic Enhancer Activity and RNA Translation to Predict Fibrosis Reversibility in Heart Failure: A Deep Learning Approach | Rifaldy Fajar (IMCDS-BRF, Indonesia) | ||
| 09:14-09:21 | Balancing Blood Pressure and Catecholamine Support Is Critical in Cardiogenic Shock Patients | Benedikt Beer (Karolinska Institutet, Sweden) | ||
| 09:21-09:28 | Phenomapping-Derived Tool to Individualize the Effect of Sacubitril/Valsartan in Heart failure with Preserved Ejection Fraction | Minjae Yoon (Seoul National Univ., Korea) | ||
| 09:28-09:35 | Myocardial Tissue Characteristics and Left Ventricular Reverse Remodeling in Non-ischemic Dilated Cardiomyopathy Implemented with Ivabradine | Jooyeon Lee (Yonsei Univ., Korea) | ||
| 09:35-09:42 | Association of Steatotic Liver Disease Subtypes with the Clinical Expression of Hypertrophic Cardiomyopathy: Insights from a Nationwide Cohort Study | Yuran Ahn (The Catholic Univ., Korea) | ||
| 09:42-09:49 | Effects of Guideline-directed Medical Therapy Adherence on Mortality and Fatal Arrhythmias in Ischemic and Non-ischemic Heart Failure with Reduced Ejection Fraction: A National Cohort Analysis | Moojun Kim (Yonsei Univ., Korea) | ||
| 09:49-09:56 | Peak VO₂ as a Predictor of Outcomes in Contemporary Heart Failure Care: Insights From a Multicentre Retrospective Cohort | Natsumi Kashimura (Juntendo Univ., Japan) | ||
| 09:56-10:03 | Impact of ECMO Support on Organ Donation and Transplant Outcomes | Jihyuk Chung (Sungkyunkwan Univ., Korea) | ||
| 10:03-10:10 | Comparing Neighborhood and Individual Socioeconomic Risk Factors in Heart Failure Prognosis: Data from the Swedish Heart Failure Registry | Valente Valeria (Karolinska Institutet, Sweden) | ||
| 10:10-10:17 | The Emerging Miracle Drug in Acute Heart Failure | Farrukh Malik (National Institute of Cardiovascular Diseases, Pakistan) | ||